X0306 4 2020-03-31 0001205922 VACCINEX, INC. VCNX 0001748346 Frieberg Jacob B. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 Common Stock 52866 D Option (Right to Acquire) Common Stock 4420 44200 D Option (Right to Acquire) Common Stock 4420 44200 I By Benbow Estates, Ltd. Option (Right to Acquire) Common Stock 4121 75000 I By Gee Eff Services Limited Stock Option (Right to Buy) 13.60 2027-09-15 Common Stock 6396 6396 D Stock Option (Right to Buy) 5.26 2029-03-30 Common Stock 2501 2501 D Stock Option (Right to Buy) 7.78 2020-05-15 Common Stock 7718 7718 D Stock Option (Right to Buy) 5.52 2019-06-30 2029-06-29 Common Stock 2385 2385 D Stock Option (Right to Buy) 7.17 2019-09-30 2029-09-27 Common Stock 1856 1856 D Stock Option (Right to Buy) 4.85 2019-12-31 2029-12-28 Common Stock 2737 2737 D Stock Option (Right to Buy) 4.00 2020-03-31 4 A 0 3336 0 A 2020-03-31 2030-03-29 Common Stock 3336 3336 D Includes 13,574 shares previously held in a trust which were distributed to Mr. Frieberg on March 1, 2019 and are now owned directly. Limited partnership units of Vaccinex Products, LP, which are presently exchangeable into shares of Common Stock on a 1-for-10 basis at the holder's option. Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Partnership interests in VX3 (DE) LP, or VX3, which are presently exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, Gee Eff Services Limited entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date. Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. Exercisable in full as of the date of this report. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2020. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. /s/ Scott E. Royer, Attorney-in-Fact for Jacob B. Frieberg 2020-04-01